Impact of Genetic Polymorphisms on Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma: A Systematic Review and Bioinformatics Analysis
4 affiliations
- 1Laboratory Medicine Department, Faculty of Applied Medical Sciences, Al-Azhar University-Gaza, Gaza Strip, Palestine.
- 2Faculty of Medicine, Mansoura University, Mansoura, Egypt.
- 3Chemical Pathology Department, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, Kubang Kerian, Malaysia.
- 4Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Abstract
Background:: Bortezomib, a 26S proteasome inhibitor, has become a cornerstone in the treatment of multiple myeloma. However, its use is limited by a common and potentially serious adverse effect, bortezomib-induced peripheral neuropathy (BIPN), which manifests in 30-60% of multiple myeloma patients primarily as a sensory, distal, axonal neuropathy, often with pain, numbness, tingling, and in some cases, motor involvement, which can lead to dose reductions, therapy discontinuation, or long-term morbidity. BIPN is associated with genetic predisposition, and several studies suggest that single-nucleotide polymorphisms (SNPs) may contribute to the protective or increased risk effects of BIPN. This study aimed to investigate the genetic basis of BIPN in multiple myeloma.
Methods:: A qualitative systematic review was conducted to determine unique SNPs with significant association with BIPN. The search was performed using PubMed, Embase, Scopus, Web of Science, Google Scholar, Cochrane Library, ScienceDirect, and ClinicalTrials.gov. The risk of bias analysis was conducted following the Q-Genie protocol. The included SNPs were computationally analyzed using Gene Ontology enrichment, KEGG, and PPI network analyses to determine pathways implicated in BIPN. SNPnexus analysis was applied, including SIFT and PolyPhen-2 functional prediction, evolutionary conservation, epigenetic regulatory mapping, significant biological pathways, and population allele frequencies.
Results:: From a total of 9 studies, 48 SNPs increase the risk of BIPN, while 21 are protective. Computational analyses revealed that SNP-associated BIPN genes are implicated in xenobiotic response, detoxification, signal transduction, and inflammatory pathways. SIFT and PolyPhen-2 identified some variants with a potential impact on protein function. Several SNPs are conserved, which reflects their functional roles. Allele frequencies are distinct, with some SNPs being rare and others showing uneven distribution across populations.
Conclusions:: Genetic variants probably play a significant role in the development of BIPN. The findings provide a mechanistic framework for predictive genotyping and personalized therapeutic strategies to mitigate BIPN in multiple myeloma patients.
Related
- Topical herbal medicine as treatment for chemotherapy-induced peripheral neuropathy: a systematic review of randomized controlled trials
- Peripheral Neuropathy in Parkinson’s Disease Treated with Device-Assisted Therapies: How Often It Is Reported Depends on How It Is Sought. A Systematic Review and Meta-Analysis
- Effect of cryotherapy on chemotherapy-induced peripheral neuropathy in patients with breast cancer treated with taxanes: a systematic review using the GRADE system.
- Experimental evidence for electroacupuncture in managing pain from chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis
- Effects of sensorimotor training on chemotherapy-induced peripheral neuropathy-related outcomes in adults with cancer: A systematic review and meta-analysis of randomized controlled trials.
BibTeX
@article{sultan2026impact,
title = {{Impact of Genetic Polymorphisms on Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma: A Systematic Review and Bioinformatics Analysis}},
author = {Nadeen S. Sultan and Ahmed S. Alhallaq and Mohammed S. Alhallaq and Heba Mohammed Arafat and Sadeen Eid and Ashraf Jaber Shaqaliah},
journal = {Asian Pacific Journal of Cancer Prevention : APJCP},
year = {2026},
month = jun,
doi = {10.31557/apjcp.2026.27.6.1967},
url = {https://doi.org/10.31557/apjcp.2026.27.6.1967},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Impact of Genetic Polymorphisms on Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma: A Systematic Review and Bioinformatics Analysis
AU - Nadeen S. Sultan
AU - Ahmed S. Alhallaq
AU - Mohammed S. Alhallaq
AU - Heba Mohammed Arafat
AU - Sadeen Eid
AU - Ashraf Jaber Shaqaliah
PY - 2026
DA - 2026/06/19
JO - Asian Pacific Journal of Cancer Prevention : APJCP
DO - 10.31557/apjcp.2026.27.6.1967
UR - https://doi.org/10.31557/apjcp.2026.27.6.1967
AB - Background:: Bortezomib, a 26S proteasome inhibitor, has become a cornerstone in the treatment of multiple myeloma. However, its use is limited by a common and potentially serious adverse effect, bortezomib-induced peripheral neuropathy (BIPN), which manifests in 30-60% of multiple myeloma patients primarily as a sensory, distal, axonal neuropathy, often with pain, numbness, tingling, and in some cases, motor involvement, which can lead to dose reductions, therapy discontinuation, or long-term morbidity. BIPN is associated with genetic predisposition, and several studies suggest that single-nucleotide polymorphisms (SNPs) may contribute to the protective or increased risk effects of BIPN. This study aimed to investigate the genetic basis of BIPN in multiple myeloma. Methods:: A qualitative systematic review was conducted to determine unique SNPs with significant association with BIPN. The search was performed using PubMed, Embase, Scopus, Web of Science, Google Scholar, Cochrane Library, ScienceDirect, and ClinicalTrials.gov. The risk of bias analysis was conducted following the Q-Genie protocol. The included SNPs were computationally analyzed using Gene Ontology enrichment, KEGG, and PPI network analyses to determine pathways implicated in BIPN. SNPnexus analysis was applied, including SIFT and PolyPhen-2 functional prediction, evolutionary conservation, epigenetic regulatory mapping, significant biological pathways, and population allele frequencies. Results:: From a total of 9 studies, 48 SNPs increase the risk of BIPN, while 21 are protective. Computational analyses revealed that SNP-associated BIPN genes are implicated in xenobiotic response, detoxification, signal transduction, and inflammatory pathways. SIFT and PolyPhen-2 identified some variants with a potential impact on protein function. Several SNPs are conserved, which reflects their functional roles. Allele frequencies are distinct, with some SNPs being rare and others showing uneven distribution across populations. Conclusions:: Genetic variants probably play a significant role in the development of BIPN. The findings provide a mechanistic framework for predictive genotyping and personalized therapeutic strategies to mitigate BIPN in multiple myeloma patients.
SN - 1513-7368
SN - 2476-762X
ER -